In addition to inhibiting COX-2 17, etodolac has COX-independent activities including inhibiting retinoid X receptor (RXRα) leading to apoptosis in cancer cells with high expression levels of the PPARγ/RXRα nuclear receptor complex 18. This evidence concerns the gene RXRA and cancer.